A non-DRE, voided urine, genomic assay to diagnose prostate cancer and to assess its aggressiveness.
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high-risk real-world prostate cancer population. The silent burden: A SEER-based analysis of potential years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results